Nanotechnological strategies to increase the oxygen content of the tumor

Junjie Zhang1, Kaiyuan Tang1, Runqi Fang1

  • 1School of Fundamental Sciences, Bengbu Medical College, Bengbu, China.

Insights

Nanotechnology offers promising strategies to combat tumor hypoxia, a condition that hinders cancer treatments. This review explores methods to improve the tumor microenvironment, deliver oxygen, and generate oxygen within tumors to enhance therapeutic outcomes.

Area of Science:

  • Oncology
  • Nanotechnology
  • Biomedical Engineering

Background:

  • Hypoxia, or low oxygen levels, is a significant negative prognostic indicator in solid tumors.
  • Tumor hypoxia increases invasiveness and reduces sensitivity to radiotherapy, chemotherapy, and photodynamic therapy.
  • Alleviating tumor hypoxia is a critical target for improving cancer treatment efficacy.

Purpose of the Study:

  • To summarize recent nanotechnological strategies for elevating oxygen levels in tumors.
  • To provide an overview of approaches for improving the hypoxic tumor microenvironment.
  • To discuss methods for oxygen delivery and generation within hypoxic tumors.

Main Methods:

  • Literature review of recent advancements in nanomedicine for tumor hypoxia.
  • Categorization of strategies into improving the tumor microenvironment, oxygen delivery, and oxygen generation.
  • Analysis of the challenges and future prospects of these nanotechnological approaches.

Main Results:

  • Nanotechnological strategies can be broadly classified into three main approaches.
  • These approaches aim to directly address oxygen deficiency within the tumor.
  • The review highlights the potential of nanotechnology to overcome treatment resistance caused by hypoxia.

Conclusions:

  • Nanotechnology presents a valuable toolkit for developing novel therapeutic strategies against tumor hypoxia.
  • Further research into these nanotechnological interventions is crucial for enhancing cancer therapy.
  • Addressing tumor hypoxia through nanotechnology holds significant promise for improving patient outcomes in oncology.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K